DNA Mutation Detection in Circulating Tumor DNA and Tissue by mmADPS for Pancreatic Cancer

Based on the cell free nucleic acid analysis information of blood samples and genetic mutation profile of EUS-FNB tissue from pancreatic cancer, the concordance between them is evaluated. And based on this information, biomarkers for diagnosis, treatment, and prognosis of pancreatic cancer are explored.

Inclusion Criteria:Patients diagnosed with pancreatic cancer through histological or radiologic examination and before treatment beginsPatients aged 18 or older who voluntarily agrees to participate in the study and is willing to understand and comply with the subsequent treatment procedures and sample collection scheduleAmong patients diagnosed with benign pancreatic diseases (pancreatic cyst, chronic pancreatitis, etc.), patients who have need for histological examination as control groupExclusion Criteria:Where the subject himself/herself refuses to fill out the consent form or is unable to fill out the consent formIf a laboratory test is impossible due to a qualitative problem with the collected blood sampleWhere the collected tissue does not contain tissue of the desired malignant or benign disease